Yes Angelo,
It'll make for interesting reading.
I also believe the royalty cut is higher during the exclusivity period ..... but the market size of the 2 newest dosages is 40% smaller than the market size of the initial two doses, and I believe there would already have been some price erosion since the original generic was introduced into the marketplace ......
Presently I am anticipating about a breakeven F1Q, plus or minus, depending on expenses for the Q.
Could be totally off base on the revenue recognition but ..... as I had previously explained to Samsa elsewhere ..... if I were to sell him a bridge today and the terms were for him to pay within 45 days ...... I would still report my sale to him on my financials for the month of March with the reasonable certainty that "he's good for it" being a standup guy and all =) ..... and I'd record a short term receivable to balance my books. If you were to receive a cut of my sale (royalty) you could reasonably estimate on your financials how much you would get from the sale and report that amount as revenue for March on your financials with a similar short term receivable just waiting on me to pay you.
Amigo Mike
News 
Market Data 
Discover 
AI
